Close menu




November 11th, 2020 | 12:22 CET

BYD, Saturn Oil & Gas, Plug Power - This news is incredible!

  • Investments
Photo credits: pixabay.com

Since Saturday, when Joe Biden was declared the 46th President of the United States of America and then on Monday afternoon with BioNTech and Pfizer announcing the positive results of the Corona vaccine tests, we seem to be living in a restored world again, at least in the stock market. The technology stocks that excited during the crisis, which benefited from digitalization and e-commerce, plummeted. By contrast, cyclical stocks from the old economy, which were boring for many, boomed again. Oil stocks also celebrated an astonishing comeback. The trend of regrouping is likely to continue.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA80412L1076 , CNE100000296 , US72919P2020

Table of contents:


    Huge step

    For the management of the Canadian oil exploration Company, Saturn Oil & Gas, last Friday was both Easter and Christmas. With Jean-Pierre Colin's commitment to join the Canadian oil exploration Company as a senior strategy consultant, the goal of becoming an innovation leader in the oil and gas industry is becoming increasingly apparent.

    40 years of concentrated experience

    The newcomer has an impressive and almost endless track record. Among other things, Colin has advised several senior politicians in the federal government and Privy Council of Canada, and five acquisitions by Petro-Canada of the country's largest oil and gas companies in the 1980s. Also, the strategist served on the boards of many successful junior commodities companies, including Pelangio Mines Inc. and Virginia Gold Inc., which sold its Eleonor project for more than $1 billion to Goldcorp Inc., now known as Newmont Corporation.

    Strong focus on acquisitions

    As stated in a press release, Colin commented: "Saturn Oil & Gas represents a unique opportunity to build an oil & gas acquisition vehicle that can provide accretive growth and returns for its shareholders and other key stakeholders." The goal of successfully making acquisitions has long been pursued by the experienced Canadian CEO, John Jeffrey. His maxim is to make acquisitions rather than develop his own drilling programs.

    Share close to breakout

    For Saturn Oil & Gas It is probably only a matter of time before the first reports of success in terms of financing or new acquisitions are received. At the moment, the paper is struggling with the CAD 0.12 mark. The trading volume has been surprisingly high in the last few days with rising prices. A short squeeze would therefore come as no surprise.

    High rating despite a rally

    Tesla's Chinese competitor continued to receive a buy rating from analyst firm, Daiwa. The price target was raised significantly from HKD 150 to HKD 250. The reason for the continued bullish mood among experts is the sharply increased profit forecasts for the fourth quarter. The new flagship Company, Han, in particular, is likely to sell like hot cakes. The analysts also expect significant sales in 2021. At the moment there are 40,000 orders for the Han. For the last two months of 2020, being November and December, 10,000 orders for each month are expected for the new flagship.

    Better than expected

    Although the fuel manufacturer Plug Power disappointed investors and analysts with its loss, the Company was able to impress in terms of sales and outlook. With a loss of USD 0.11, the Company fell short of analysts' forecasts. The analysts bet on a loss of only minus USD 0.07. In contrast, sales were significantly better than expected at USD 125.6 million. The forecast here was only USD 106.5 million.

    Outlook and "Green Deal"

    Plug Power remains optimistic that it will be able to achieve its medium-term goals. The sales target for 2024 is USD 1.2 billion, followed by an operating profit of around USD 200 million and an adjusted EBITDA margin of over 20%. With the green deal announced by the new US president, these forecasts appear to be quite realistic.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read